Myrto Chatzopoulou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Myrto Chatzopoulou has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Julia Rode
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
3 shared publications - Robert Jan Brummer
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
3 shared publications - Ana Cristina Calzada-Rascón
Instituto Mexicano del Seguro Social, Hospital General de Zona No. 47 Vicente Guerrero, Servicio de Medicina Interna. Ciudad de México, México
2 shared publications - Ashley N Hutchinson2 shared publications
- Cecilia Bergh
Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden
2 shared publications - Işılay Kaya2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e94648
Effects of a Nutritionally Balanced Between-Meal Food Product on Brain Function in Older Adults: Protocol for a Randomized Controlled Trial (the MiniMeal Study)
Background: Increasing evidence suggests that diet influences gut microbiota composition and systemic inflammation, which in turn may affect brain health, cognitive function, and mood regulation. Elevated levels of systemic inflammation have been associated with reduced resting-state functional connectivity within the default mode network, a pattern linked to poorer cognitive performance in older adults. Dietary interventions incorporating anti-inflammatory foods, such as oat bran and chickpeas, may help attenuate low-grade inflammation and promote healthier dietary behaviors in aging populations. Objective: This study protocol describes a randomized controlled trial designed to investigate the effect of healthy between-meal products on brain activity in older adults. Methods: The MiniMeal study is a 9-week, 3-arm randomized controlled trial comprising a blinded, 2-arm intervention and a nonblinded, no-intervention comparison group. A total of 114 community-dwelling men and women aged ≥70 years (38 per group) will be randomized to 1 of 3 study arms. Participants in the intervention group will consume the MiniMeal products, while those in the reference or control group will receive reference or control products. In both intervention arms, products will be consumed twice daily, either replacing or supplementing habitual morning, afternoon, or evening between-meal occasions. All other dietary habits will remain unchanged. Participants in the no-intervention group will maintain their habitual diet throughout the study period. The primary outcome is functional brain activity, assessed using functional magnetic resonance imaging during the n-back task, comparing the intervention and reference groups. Secondary outcomes include comparisons with the no-intervention group and assessment of other neural measures, biomarkers in blood, body composition, physical function, and self-reported well-being. Results: Ethics approval was obtained from the Swedish Ethical Review Authority (Etikprövningsmyndigheten) on February 20, 2024. Participant recruitment was completed on December 18, 2025. Data collection was completed by February 27, 2026. Data analysis is ongoing since January 7, 2026. A total of 114 participants were enrolled, of whom, 106 completed all 6 study visits. Conclusions: This study will provide insights into whether nutritious between-meal products influence brain function in older adults and will explore potential underlying biological mechanisms. The findings are expected to contribute to a better understanding of the relationship between dietary habits and cognitive health in older adults and may inform future research on diet-based strategies to support in healthy aging. Trial Registration: ClinicalTrials.gov NCT06353984; https://clinicaltrials.gov/study/NCT06353984 International Registered Report Identifier (IRRID): DERR1-10.2196/94648
- 17 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e94648
Open AccessEffects of a Nutritionally Balanced Between-Meal Food Product on Brain Function in Older Adults: Protocol for a Randomized Controlled Trial (the MiniMeal Study)
Background: Increasing evidence suggests that diet influences gut microbiota composition and systemic inflammation, which in turn may affect brain health, cognitive function, and mood regulation. Elevated levels of systemic inflammation have been associated with reduced resting-state functional connectivity within the default mode network, a pattern linked to poorer cognitive performance in older adults. Dietary interventions incorporating anti-inflammatory foods, such as oat bran and chickpeas, may help attenuate low-grade inflammation and promote healthier dietary behaviors in aging populations. Objective: This study protocol describes a randomized controlled trial designed to investigate the effect of healthy between-meal products on brain activity in older adults. Methods: The MiniMeal study is a 9-week, 3-arm randomized controlled trial comprising a blinded, 2-arm intervention and a nonblinded, no-intervention comparison group. A total of 114 community-dwelling men and women aged ≥70 years (38 per group) will be randomized to 1 of 3 study arms. Participants in the intervention group will consume the MiniMeal products, while those in the reference or control group will receive reference or control products. In both intervention arms, products will be consumed twice daily, either replacing or supplementing habitual morning, afternoon, or evening between-meal occasions. All other dietary habits will remain unchanged. Participants in the no-intervention group will maintain their habitual diet throughout the study period. The primary outcome is functional brain activity, assessed using functional magnetic resonance imaging during the n-back task, comparing the intervention and reference groups. Secondary outcomes include comparisons with the no-intervention group and assessment of other neural measures, biomarkers in blood, body composition, physical function, and self-reported well-being. Results: Ethics approval was obtained from the Swedish Ethical Review Authority (Etikprövningsmyndigheten) on February 20, 2024. Participant recruitment was completed on December 18, 2025. Data collection was completed by February 27, 2026. Data analysis is ongoing since January 7, 2026. A total of 114 participants were enrolled, of whom, 106 completed all 6 study visits. Conclusions: This study will provide insights into whether nutritious between-meal products influence brain function in older adults and will explore potential underlying biological mechanisms. The findings are expected to contribute to a better understanding of the relationship between dietary habits and cognitive health in older adults and may inform future research on diet-based strategies to support in healthy aging. Trial Registration: ClinicalTrials.gov NCT06353984; https://clinicaltrials.gov/study/NCT06353984 International Registered Report Identifier (IRRID): DERR1-10.2196/94648
- Open Access
- 4 March 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Effects of a Nutritionally Balanced Between-Meal Food Product on Brain Function in Older Adults: Protocol for a Randomized Controlled Trial (the MiniMeal Study) (Preprint)
BACKGROUND Increasing evidence suggests that diet influences gut microbiota composition and systemic inflammation, which in turn may affect brain health, cognitive function, and mood regulation. Elevated levels of systemic inflammation have been associated with reduced resting-state functional connectivity within the default mode network, a pattern linked to poorer cognitive performance in older adults. Dietary interventions incorporating anti-inflammatory foods, such as oat bran and chickpeas, may help attenuate low-grade inflammation and promote healthier dietary behaviors in aging populations. OBJECTIVE This study protocol describes a randomized controlled trial designed to investigate the effect of healthy between-meal products on brain activity in older adults. METHODS The MiniMeal study is a 9-week, 3-arm randomized controlled trial comprising a blinded, 2-arm intervention and a nonblinded, no-intervention comparison group. A total of 114 community-dwelling men and women aged ≥70 years (38 per group) will be randomized to 1 of 3 study arms. Participants in the intervention group will consume the MiniMeal products, while those in the reference or control group will receive reference or control products. In both intervention arms, products will be consumed twice daily, either replacing or supplementing habitual morning, afternoon, or evening between-meal occasions. All other dietary habits will remain unchanged. Participants in the no-intervention group will maintain their habitual diet throughout the study period. The primary outcome is functional brain activity, assessed using functional magnetic resonance imaging during the n-back task, comparing the intervention and reference groups. Secondary outcomes include comparisons with the no-intervention group and assessment of other neural measures, biomarkers in blood, body composition, physical function, and self-reported well-being. RESULTS Ethics approval was obtained from the Swedish Ethical Review Authority (Etikprövningsmyndigheten) on February 20, 2024. Participant recruitment was completed on December 18, 2025. Data collection was completed by February 27, 2026. Data analysis is ongoing since January 7, 2026. A total of 114 participants were enrolled, of whom, 106 completed all 6 study visits. CONCLUSIONS This study will provide insights into whether nutritious between-meal products influence brain function in older adults and will explore potential underlying biological mechanisms. The findings are expected to contribute to a better understanding of the relationship between dietary habits and cognitive health in older adults and may inform future research on diet-based strategies to support in healthy aging. CLINICALTRIAL ClinicalTrials.gov NCT06353984; https://clinicaltrials.gov/study/NCT06353984 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/94648
- 4 March 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffects of a Nutritionally Balanced Between-Meal Food Product on Brain Function in Older Adults: Protocol for a Randomized Controlled Trial (the MiniMeal Study) (Preprint)
BACKGROUND Increasing evidence suggests that diet influences gut microbiota composition and systemic inflammation, which in turn may affect brain health, cognitive function, and mood regulation. Elevated levels of systemic inflammation have been associated with reduced resting-state functional connectivity within the default mode network, a pattern linked to poorer cognitive performance in older adults. Dietary interventions incorporating anti-inflammatory foods, such as oat bran and chickpeas, may help attenuate low-grade inflammation and promote healthier dietary behaviors in aging populations. OBJECTIVE This study protocol describes a randomized controlled trial designed to investigate the effect of healthy between-meal products on brain activity in older adults. METHODS The MiniMeal study is a 9-week, 3-arm randomized controlled trial comprising a blinded, 2-arm intervention and a nonblinded, no-intervention comparison group. A total of 114 community-dwelling men and women aged ≥70 years (38 per group) will be randomized to 1 of 3 study arms. Participants in the intervention group will consume the MiniMeal products, while those in the reference or control group will receive reference or control products. In both intervention arms, products will be consumed twice daily, either replacing or supplementing habitual morning, afternoon, or evening between-meal occasions. All other dietary habits will remain unchanged. Participants in the no-intervention group will maintain their habitual diet throughout the study period. The primary outcome is functional brain activity, assessed using functional magnetic resonance imaging during the n-back task, comparing the intervention and reference groups. Secondary outcomes include comparisons with the no-intervention group and assessment of other neural measures, biomarkers in blood, body composition, physical function, and self-reported well-being. RESULTS Ethics approval was obtained from the Swedish Ethical Review Authority (Etikprövningsmyndigheten) on February 20, 2024. Participant recruitment was completed on December 18, 2025. Data collection was completed by February 27, 2026. Data analysis is ongoing since January 7, 2026. A total of 114 participants were enrolled, of whom, 106 completed all 6 study visits. CONCLUSIONS This study will provide insights into whether nutritious between-meal products influence brain function in older adults and will explore potential underlying biological mechanisms. The findings are expected to contribute to a better understanding of the relationship between dietary habits and cognitive health in older adults and may inform future research on diet-based strategies to support in healthy aging. CLINICALTRIAL ClinicalTrials.gov NCT06353984; https://clinicaltrials.gov/study/NCT06353984 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/94648
- Open Access
- 21 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1) , 73
Development of a novel humanized gut-brain axis model as a tool toward personalized nutrition
Intestinal luminal microbial metabolites affect tryptophan and serotonin metabolism, and cross or modify the blood-brain barrier (BBB). Understanding those mechanisms further necessitates integrated gut-brain axis model systems. Using an ex vivo-in vitro approach, H 2 O 2- stressed or non-stressed human dermal fibroblasts – representing the BBB – are cultured with serosal fluids of healthy or irritable bowel syndrome human colonic biopsies collected from Ussing chamber experiments, after participant’s colon was exposed to butyrate in vivo, fecal fiber fermentation or control supernatant ex vivo. Culturing fibroblasts with serosal fluids does not compromise viability or have cytotoxic effects. Serosal fluids alone do not alter expression of tryptophan-related large amino acid membrane transporter genes and proteins, nor their activity ( i.e., tryptophan uptake). However, adding serosal fluids to fibroblasts prior to oxidative stress indicate a protective role. This new model allows investigation of direct effects of serosal content on BBB-representing fibroblasts and is highly promising for more personalized applications.
- 21 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1) , 73
Open AccessDevelopment of a novel humanized gut-brain axis model as a tool toward personalized nutrition
Intestinal luminal microbial metabolites affect tryptophan and serotonin metabolism, and cross or modify the blood-brain barrier (BBB). Understanding those mechanisms further necessitates integrated gut-brain axis model systems. Using an ex vivo-in vitro approach, H 2 O 2- stressed or non-stressed human dermal fibroblasts – representing the BBB – are cultured with serosal fluids of healthy or irritable bowel syndrome human colonic biopsies collected from Ussing chamber experiments, after participant’s colon was exposed to butyrate in vivo, fecal fiber fermentation or control supernatant ex vivo. Culturing fibroblasts with serosal fluids does not compromise viability or have cytotoxic effects. Serosal fluids alone do not alter expression of tryptophan-related large amino acid membrane transporter genes and proteins, nor their activity ( i.e., tryptophan uptake). However, adding serosal fluids to fibroblasts prior to oxidative stress indicate a protective role. This new model allows investigation of direct effects of serosal content on BBB-representing fibroblasts and is highly promising for more personalized applications.